Arbutus Biopharma Corporation Et Al V. Moderna, Inc. Et Al
Arbutus Biopharma Corporation and Genevant Sciences GmbH have filed a lawsuit against Moderna for infringing on their patented technology for lipid nanoparticle delivery platforms. This technology is crucial for the success of mRNA-based vaccines like Moderna’s COVID-19 vaccine. Despite being aware of Arbutus’s patents and licensing them for other product programs, Moderna chose not to license the technology for its COVID-19 vaccine and instead used it without permission or compensation. The lawsuit seeks fair compensation for the use of their patented technology without seeking an injunction or impeding the sale or manufacture of Moderna’s vaccine. Arbutus claims that Moderna's COVID-19 vaccine could not have been developed without their patented LNP delivery technology, which Moderna used without authorization.
Read Next